Yue C Wang

US Patent:

6728396, Apr 27, 2004

Filed:

Feb 24, 2003

Appl. No.:

10/370565

Inventors:

Yue Joseph Wang - North Potomac MD

Assignee:

Catholic University of America - Washington DC

International Classification:

G06K 900

US Classification:

382129, 128922

Abstract:

The present invention describes a partial independent component analysis (PICA) technique for blindly separating partially independent and/or gaussian-like sources from mixed observations over an informative index subspace, which allows various applications in independent component imaging. The present invention estimates a demixing matrix using only the independent and/or nongaussian portion of the observations. Specifically, rather than using all the data points which give rise to a large separation error, a subset of the data points is identified such that the partial source profiles defined over such a subset are statistically independent and/or nongaussian. The present invention describes a complete implementation of such a technique, whose steps and parameters may be achieved and estimated using an information theoretic-based neural computational algorithm. The present invention also demonstrates the principle of the approach on both controlled cases and real-world problems, and describes many extended applications of such a technique.

US Patent:

20220411509, Dec 29, 2022

Filed:

Apr 29, 2022

Appl. No.:

17/661307

Inventors:

- Gaithersburg MD, US
Yue WANG - Gaithersburg MD, US
Gordon MOODY - Gaithersburg MD, US
Deepali MALHOTRA - Gaithersburg MD, US
Michael OVERSTREET - Gaithersburg MD, US
Eleanor CLANCY-THOMPSON - Giathersburg MD, US
Karin LEE - Gaithersburg MD, US
Stacy PRYTS - Gaithersburg MD, US
Scott HAMMOND - Gaithersburg MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

C07K 16/28
A61K 45/06
A61K 39/395
A61P 35/00

Abstract:

The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.

US Patent:

20190241659, Aug 8, 2019

Filed:

Nov 8, 2018

Appl. No.:

16/184251

Inventors:

- Gaithersburg MD, US
YUE WANG - GAITHERSBURG MD, US
RYAN GILBRETH - GAITHERSBURG MD, US
RONALD HERBST - GAITHERSBURG MD, US
SCOTT HAMMOND - GAITHERSBURG MD, US
MICHAEL OBERST - GAITHERSBURG MD, US
GODFREY JONAH RAINEY - Gaithersburg MD, US
SIMON DOVEDI - CAMBRIDGE, GB
JONATHAN SEAMAN - CAMBRIDGE, GB
MICHELLE TURNHAM - CAMBRIDGE, GB

International Classification:

C07K 16/28
A61K 39/395
A61P 35/00
A61K 45/06

Abstract:

Provided herein are bispecific fusion proteins and methods of using the bispecific fusion proteins for treating cancer.

US Patent:

20150044168, Feb 12, 2015

Filed:

Mar 11, 2013

Appl. No.:

14/384714

Inventors:

- Gaithersburg MD, US
Volker Armin Knappertz - Potomac MD, US
Laura Lee Carter - Ann Arbor MI, US
Yue Wang - Gaithersburg MD, US

International Classification:

C07K 16/28
A61K 45/06
A61K 39/395

US Classification:

424 856, 4241331, 4241441, 4241811

Abstract:

The present invention provides for the treatment of multiple sclerosis through the use of chimeric and humanized versions of anti-CD19 antibodies that may mediate ADCC, CDC, and/or apoptosis.